ライフサイエンスコーパス: cholinesterase inhibitor

1 and were treated for at least 1 month with a cholinesterase inhibitor.

2 rase system, and achieve effective dual FAAH/cholinesterase inhibitors.

3 r is as a promising new tool for analysis of cholinesterase inhibitors.

4 in locomotion behavior and responsiveness to cholinesterase inhibitors.

5 onsidered, concentrating upon studies of the cholinesterase inhibitors.

6 ly accessible both for the substrate and for cholinesterase inhibitors.

7 was no difference in efficacy among various cholinesterase inhibitors.

8 ntine or when to co-prescribe memantine with cholinesterase inhibitors.

9 orted by an improvement of these symptoms by cholinesterase inhibitors.

10 detection of organophosphates or exposure to cholinesterase inhibitors.

11 lzheimer's dementia is commonly treated with cholinesterase inhibitors [4-7]; however, these are mode

12 vention patients were more likely to receive cholinesterase inhibitors (79.8% vs 55.1%; P = .002) and

13 organophosphorus compounds (OPs) are potent cholinesterase inhibitors, accounting for their use as i

14 We show that a brief treatment with the cholinesterase inhibitor aldicarb induces a form of pres

15 Pharmacological assays using the cholinesterase inhibitor aldicarb suggest that VAs and G

16 have an exaggerated paralytic response to a cholinesterase inhibitor, aldicarb.

17 tter addressed by multifunctional drugs than cholinesterase inhibitors alone.

18 Physostigmine (a centrally active cholinesterase inhibitor) also dose-dependently inhibite

19 d to determine the effects of galantamine, a cholinesterase inhibitor and a nicotinic allosteric pote

20 cluding a phenserine analogue as a potential cholinesterase inhibitor and constrained tryptamine deri

21 y measured the effects of treatment with the cholinesterase inhibitor and nicotinic receptor modulato

22 mal limb muscles, response to treatment with cholinesterase inhibitors and 3,4-diaminopyridine, and t

23 er of direct acting muscarinic agonists, two cholinesterase inhibitors and a putative m1 agonist/musc

24 Cholinesterase inhibitors and corticosteroids have been

25 Cholinesterase inhibitors and memantine do not have regu

26 for randomised, placebo-controlled trials on cholinesterase inhibitors and memantine in patients with

27 sess the evidence for efficacy and safety of cholinesterase inhibitors and memantine in vascular deme

28 Cholinesterase inhibitors and memantine produce small be

29 Cognitive enhancing drugs, such as cholinesterase inhibitors and methylphenidate, are used

30 ortant implications for the long-term use of cholinesterase inhibitors and other cholinomimetics in t

31 Evidence regarding the benefits of cholinesterase inhibitors and other therapeutic options

32 ning the interaction between carbamate-based cholinesterase inhibitors and their enzyme target.

33 preservation of the cholinergic system (via cholinesterase inhibitors) and hippocampal neurons (via

34 Antipsychotics, cholinesterase inhibitors, and alpha-2 agonists are the

35 Short-term treatment with a cholinesterase inhibitor appears to enhance the activity

36 cotinic cholinergic agonists are used, or if cholinesterase inhibitors are combined with other agents

37 Cholinesterase inhibitors are commonly used to improve c

38 results from randomized controlled trials of cholinesterase inhibitors are conflicting.

39 More effective treatments than cholinesterase inhibitors are needed for Alzheimer's dis

40 erate clinically detected Alzheimer disease, cholinesterase inhibitors are somewhat effective in slow

41 Cholinesterase inhibitors are the primary treatment for

42 , and fewer than 20% of patients stop taking cholinesterase inhibitors because of side effects.

43 , diarrhoea, and insomnia) occurred with the cholinesterase inhibitors, but not with memantine.

44 ifos and diazinon are bioactivated to potent cholinesterase inhibitors by cytochrome P-450 systems.

45 results indicate that one mechanism by which cholinesterase inhibitors can improve memory is by enhan

46 Phenserine, a recently developed cholinesterase inhibitor (ChEI), has been reported to re

47 nd visual) were also affected in MCI and (2) cholinesterase inhibitors (ChEIs), one of the therapies

48 Therefore, use of a cholinesterase inhibitor (ChI) might improve cognitive f

49 Administration of a central cholinesterase inhibitor (ChI) partially restored the su

50 Cholinesterase inhibitor (ChI) therapy for mixed dementi

51 In persons with MCI, cholinesterase inhibitors did not reduce dementia risk (

52 while neostigmine (a peripherally restricted cholinesterase inhibitor) did not.

53 he brains of healthy human subjects with the cholinesterase inhibitor donepezil (trade name: Aricept)

54 zed by fusing the pharmacophoric features of cholinesterase inhibitor donepezil and diarylthiazole as

55 found that cholinergic enhancement with the cholinesterase inhibitor donepezil improved target detec

56 The cholinesterase inhibitor donepezil was administered to n

57 Cholinesterase inhibitor drugs improve cognition and neu

58 In contrast, a cholinesterase inhibitor, eserine, although significantl

59 Stable use of cholinesterase inhibitors, estrogen, low-dose aspirin, a

60 um samples from individuals asymptomatic for cholinesterase inhibitor exposure were analyzed using th

61 Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-m

62 magnetic scavenging technique for extracting cholinesterase inhibitors from aqueous matrixes using bi

63 r a psychopharmacological challenge with the cholinesterase inhibitor galantamine (Reminyl).

64 trials of memantine in patients receiving a cholinesterase inhibitor have been performed.

65 These results indicate that cholinesterase inhibitors have a modest beneficial impac

66 PSP, but trials of cholinergic agonists and cholinesterase inhibitors have failed to show improvemen

67 Cholinesterase inhibitors improve attention, as well as

68 Cholinesterase inhibitors improve cognitive outcomes in

69 ompared with placebo, patients randomized to cholinesterase inhibitors improved 0.1 SDs on ADL scales

70 ompared with placebo, patients randomized to cholinesterase inhibitors improved 1.72 points on the NP

71 treatment effects associated with the use of cholinesterase inhibitors in these populations.

72 Treatment with cholinesterase inhibitors is well tolerated by most pati

73 ver, a combination of an M2 antagonist and a cholinesterase inhibitor may reach the maximal disease-m

74 h cognitive and behavioral disturbances, and cholinesterase inhibitors may improve behavior in Alzhei

75 Our findings suggest that treatment with cholinesterase inhibitors may improve muscle function in

76 Cholinesterase inhibitors may improve symptoms of dement

77 The cholinesterase inhibitor methyl paraoxon significantly d

78 Six to 12 months of treatment with cholinesterase inhibitors modestly slows the decline of

79 Known adverse events of cholinesterase inhibitors (nausea, vomiting, anorexia) w

80 with NAC in combination with the peripheral cholinesterase inhibitor neostigmine showed prolonged su

81 In the presence of the cholinesterase inhibitor neostigmine, EFS led to an addi

82 ceptor (mAChR) agonist, oxotremorine, or the cholinesterase inhibitor, neostigmine (NEOS), in the rRP

83 ny patients' preference to take memantine or cholinesterase inhibitors off-label rather than particip

84 te administration of rivastigmine, a central cholinesterase inhibitor, on patterns of brain activatio

85 Central Register and/or by prescription of a cholinesterase inhibitor or memantine hydrochloride from

86 cision to initiate a trial of therapy with a cholinesterase inhibitor or memantine on individualized

87 Concomitant treatment with cholinesterase inhibitors or memantine was permitted.

88 The effect of cholinesterase inhibitors or other treatments on persons

89 from our laboratory have shown that a novel cholinesterase inhibitor, phenserine, reduces betaAPP le

90 However, the administration of neither the cholinesterase inhibitor physostigmine nor the benzodiaz

91 We studied the effect of the cholinesterase inhibitor physostigmine on subcomponents

92 ith age, and attenuation by the nonselective cholinesterase inhibitor physostigmine, but no attenuati

93 artially susceptible to improvement with the cholinesterase inhibitor physostigmine.

94 Cholinesterase inhibitors positively affect cognition in

95 Cholinesterase inhibitors produce small improvements in

96 rior administration of muscarinic agonist or cholinesterase inhibitor) produced robust but transient

97 Donepezil, a cholinesterase inhibitor, restored performance in animal

98 The cholinesterase inhibitors rivastigmine, donepezil, and m

99 Whether a cholinesterase inhibitor should be used as augmentation

100 rophosphate (DCP), a model organophosphorous cholinesterase inhibitor simulant.

101 The cholinesterase inhibitors, tacrine and physostigmine, an

102 Unlike other cholinesterase inhibitors tested, rivastigmine inhibited

103 t dimethoxybenzilidene anabaseine (DMXB) and cholinesterase inhibitor tetrahydroaminoacridine (THA) w

104 We tested the premise that cholinesterase inhibitor therapy should target butyrylch

105 ia responds poorly to nonpharmacological and cholinesterase inhibitor therapy, and although corticost

106 The use of cholinesterase inhibitors to correct the cholinergic def

107 ddition, we need to know when to switch from cholinesterase inhibitors to memantine or when to co-pre

108 blocking drugs and encapsulates them, making cholinesterase inhibitors unnecessary.

109 Galantamine, a cholinesterase inhibitor used in Alzheimer's disease, si

110 Rivastigmine, a cholinesterase inhibitor, was tested in a group of clini

111 effects of metrifonate, a second generation cholinesterase inhibitor, were examined on CA1 pyramidal

112 ucted to assess the impact of galantamine, a cholinesterase inhibitor with nicotinic-receptor-modulat